{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:33:12Z","timestamp":1794666792837,"version":"4.9.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12376"],"award-info":[{"award-number":["12376"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UL2011-5336"],"award-info":[{"award-number":["UL2011-5336"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1136\/ijgc-2020-001822","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T17:00:16Z","timestamp":1603213216000},"page":"594-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":187,"title":["Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct00492778","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03469674","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03517449","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03884101","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02912572","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03951415","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6403-0143","authenticated-orcid":false,"given":"Anne Sophie V M","family":"van den Heerik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-4753","authenticated-orcid":false,"given":"Nanda","family":"Horeweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalling","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carien L","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001822_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0015","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0020","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.ejca.2015.05.015","article-title":"Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--a pooled analysis of PORTEC 1 and 2 trials","volume":"51","author":"Bosse","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0025","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0030","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-001822_bb0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(08)61767-5","article-title":"Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis","volume":"373","author":"ASTEC\/EN.5 Study Group","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-001822_bb0040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.ijrobp.2011.04.014","article-title":"External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study","volume":"82","author":"Sorbe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-001822_bb0045","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"Nout","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-001822_bb0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-8258(03)00126-4","article-title":"Survival after relapse in patients with endometrial cancer: results from a randomized trial","volume":"89","author":"Creutzberg","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0055","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-001822_bb0060","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ijrobp.2005.03.007","article-title":"Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review","volume":"63","author":"Scholten","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-001822_bb0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2015.08.023","article-title":"Long-term impact of endometrial cancer diagnosis and treatment on health-related quality of life and cancer survivorship: results from the randomized PORTEC-2 trial","volume":"93","author":"de Boer","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-001822_bb0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ygyno.2004.08.019","article-title":"Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium","volume":"95","author":"Creasman","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"24","author":"Randall","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0080","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2007.09.029","article-title":"Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study","volume":"108","author":"Susumu","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0090","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2010.06.002","article-title":"Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies","volume":"46","author":"Hogberg","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0095","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-Intermediate and high-risk early stage endometrial cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0105","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0110","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-001822_bb0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0120","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1470-2045(16)30120-6","article-title":"Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial","volume":"17","author":"de Boer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0125","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0360-3016(01)01566-8","article-title":"Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy","volume":"50","author":"Mundt","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-001822_bb0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2015.07.096","article-title":"Management of nodal recurrences of endometrial cancer with IMRT","volume":"139","author":"Ho","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0135","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.prro.2012.03.013","article-title":"Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer","volume":"3","author":"Shirvani","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.prro.2013.07.002","article-title":"Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer","volume":"4","author":"Townamchai","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0145","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0150","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.19.02381","article-title":"Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: a report from the NRG Oncology RTOG 1203 study","volume":"38","author":"Yeung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0155","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2009.06.005","article-title":"A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer","volume":"114","author":"Secord","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2012.03.011","article-title":"The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer","volume":"85","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-001822_bb0165","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/ijgc-2020-001379","article-title":"Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium","volume":"30","author":"Nasioudis","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0170","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2020-001822_bb0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0090-8258(03)00323-8","article-title":"Slide review in gynecologic oncology ensures completeness of reporting and diagnostic accuracy","volume":"90","author":"Khalifa","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0180","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/annonc\/mdx753","article-title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","volume":"29","author":"de Boer","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0185","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0360-3016(01)02710-9","article-title":"Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system","volume":"52","author":"Scholten","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-2020-001822_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/his.13871","article-title":"Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer","volume":"75","author":"Peters","year":"2019","journal-title":"Histopathology"},{"key":"10.1136\/ijgc-2020-001822_bb0195","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1080\/0284186X.2019.1643036","article-title":"Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study","volume":"58","author":"St\u00e5lberg","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2020-001822_bb0205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2020-001822_bb0210","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju402","article-title":"Prognostic significance of POLE proofreading mutations in endometrial cancer","volume":"107","author":"Church","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2020-001822_bb0215","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an antitumor immune response in endometrial cancer","volume":"21","author":"van Gool","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001822_bb0220","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0225","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001822_bb0230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0235","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-20-0149","article-title":"Integrated image-based immune and molecular profiling refines prognostication in early-stage endometrial cancer","author":"Horeweg","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/ijgc-2020-001822_bb0240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0245","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ygyno.2012.01.049","article-title":"Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer \u2264 70 years","volume":"125","author":"Leenen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0250","article-title":"Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma","author":"Brett","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2020-001822_bb0255","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001822_bb0260","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2020-001822_bb0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/his.14015","article-title":"Incorporation of molecular characteristics into endometrial cancer management","volume":"76","author":"Vermij","year":"2020","journal-title":"Histopathology"},{"key":"10.1136\/ijgc-2020-001822_bb0270","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2020-001822_bb0275","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1158\/1078-0432.CCR-17-0566","article-title":"Amplification of 1q32.1 refines the molecular classification of endometrial carcinoma","volume":"23","author":"Depreeuw","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001822_bb0280","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0285","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0290","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of promise: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2020-001822_bb0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2018.07.020","article-title":"Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial","volume":"151","author":"Wortman","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2020-001822_bb0305","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Keir","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ijgc-2020-001822_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102973","article-title":"PARP and PD-1\/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer","volume":"152","author":"Post","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-2020-001822_bb0315","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2020-001822_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0325","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0330","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2019.37.15_suppl.5501","article-title":"Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601)","volume":"37","author":"Antill","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9080109","article-title":"Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors","volume":"9","author":"Lim","year":"2017","journal-title":"Cancers"},{"key":"10.1136\/ijgc-2020-001822_bb0340","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001822_bb0345","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/13543784.2018.1558202","article-title":"Investigational PI3K\/Akt\/mTOR inhibitors in development for endometrial cancer","volume":"28","author":"Barra","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1136\/ijgc-2020-001822_bb0350","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0355","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001822_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-001822_bb0365","first-page":"39","article-title":"Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it","volume":"26","author":"Menderes","year":"2018","journal-title":"Discov Med"},{"key":"10.1136\/ijgc-2020-001822_bb0370","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0375","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0380","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001822_bb0385","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.cdd.4402148","article-title":"Cell death modalities: classification and pathophysiological implications","volume":"14","author":"Galluzzi","year":"2007","journal-title":"Cell Death Differ"},{"key":"10.1136\/ijgc-2020-001822_bb0390","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.adro.2018.08.017","article-title":"The DNA damage response in immunotherapy and radiation","volume":"3","author":"Samstein","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1136\/ijgc-2020-001822_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00505","article-title":"Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses - pre-clinical evidence and ongoing clinical applications","volume":"6","author":"Derer","year":"2015","journal-title":"Front Immunol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24023107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:39:06Z","timestamp":1753101546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24023107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1048891X24023107"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001822","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https:\/\/creativecommons.org\/licenses\/by\/4.0\/.","name":"copyright","label":"Copyright"}]}}